Skip to main content
Erschienen in: World Journal of Urology 4/2008

01.08.2008 | Topic Paper

Tissue engineered testicular prostheses with prolonged testosterone release

verfasst von: Atlantida M. Raya-Rivera, Carlos Baez, Anthony Atala, James J. Yoo

Erschienen in: World Journal of Urology | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Bilateral anorchia, either congenital or acquired, often requires testicular prostheses placement and testosterone supplementation. Several types of testosterone compounds and various modes of hormone delivery are currently used clinically, however, their pharmacokinetic properties are not ideal. In this study, we explored the possibility of creating hormone releasing testicular prostheses that could continuously supply and maintain physiologic levels of testosterone in vivo over time.

Methods

Chondrocytes, harvested from bovine articular cartilage, were seeded on testicular shaped polymer scaffolds at a concentration of 100 × 106 ml−1. The scaffolds were maintained in a bioreactor for 4 weeks to form cartilage tissue. Subsequently, testosterone enanthate (100 µg) was injected into the central hollow space of each testicular prosthesis, and maintained for 40 weeks in culture. A sample of the medium was collected every 2 days for testosterone assays. Another group of ex vivo engineered testicular prostheses was implanted into the scrotal space of castrated athymic mice (n = 10). Intratesticular injection of testosterone enanthate was made into each prosthesis at a concentration of 100 µg. Control groups consisted of animals with castration only (n = 8) and sham operations (n = 5). Testosterone levels were measured prior and 2 weeks after castration, 1 day after testosterone administration, and weekly up to 14 weeks. The engineered testicular prostheses were retrieved at sacrifice for histomorphological and immunocytochemical analyses.

Results

Milky white cartilage testicular protheses were formed by 4 weeks. The ex vivo prostheses showed an initial burst effect of testosterone followed by a broad plateau for 16 weeks (>500 ng/dl) and a decreased level of testosterone until 40 weeks. The testosterone levels were physiologic throughout 40 weeks and the entire testosterone released was calculated as 60% of the injected volume. The circulating testosterone levels in the protheses implanted animals demonstrated a maximum peak on day 1 and a continued physiologic range during the entire study period. Histologically, the retrieved testicular implants showed mature chondrocytes with a hollow center in each prosthesis.

Conclusion

This study demonstrates that engineered cartilage testis can be created in bioreactors, can be implanted in vivo, and can release testosterone for a prolonged period. Furthermore, the levels of testosterone release can be maintained within the physiologic range. Periodic reinjection may potentially provide permanent physiologic hormonal replacement. This novel technology may be beneficial for patients who require testicular prostheses and chronic hormone supplementation.
Literatur
1.
Zurück zum Zitat Adshead J, Khoubehi B, Wood J et al (2001) Testicular implants and patient satisfaction: a questionnaire-based study of men after orchidectomy for testicular cancer. BJU Int 88:559PubMedCrossRef Adshead J, Khoubehi B, Wood J et al (2001) Testicular implants and patient satisfaction: a questionnaire-based study of men after orchidectomy for testicular cancer. BJU Int 88:559PubMedCrossRef
2.
Zurück zum Zitat Baumrucker GO (1956) Testicular prosthesis for an intracapsular orchiectomy. Postgrad Semin Am Urol Assoc North Cent 55:73 Baumrucker GO (1956) Testicular prosthesis for an intracapsular orchiectomy. Postgrad Semin Am Urol Assoc North Cent 55:73
3.
Zurück zum Zitat Hazzard CT (1953) The development of a new testicular prosthesis. J Urol 70:959PubMed Hazzard CT (1953) The development of a new testicular prosthesis. J Urol 70:959PubMed
4.
Zurück zum Zitat Incrocci L, Bosch JL, Slob AK (1999) Testicular prostheses: body image and sexual functioning. BJU Int 84:1043PubMedCrossRef Incrocci L, Bosch JL, Slob AK (1999) Testicular prostheses: body image and sexual functioning. BJU Int 84:1043PubMedCrossRef
5.
Zurück zum Zitat Money J, Sollod R (1978) Body image, plastic surgery (prosthetic testes) and Kallmann’s syndrome. Br J Med Psychol 51:91PubMed Money J, Sollod R (1978) Body image, plastic surgery (prosthetic testes) and Kallmann’s syndrome. Br J Med Psychol 51:91PubMed
6.
Zurück zum Zitat Barrett DM, O’Sullivan DC, Malizia AA et al (1991) Particle shedding and migration from silicone genitourinary prosthetic devices. J Urol 146:319PubMed Barrett DM, O’Sullivan DC, Malizia AA et al (1991) Particle shedding and migration from silicone genitourinary prosthetic devices. J Urol 146:319PubMed
7.
Zurück zum Zitat Doherty AP, Mannion EM, Moss J et al (2000) Spread of silicone to inguinal lymph nodes from a leaking testicular prosthesis: a cause for chronic fatigue? BJU Int 86:1090PubMedCrossRef Doherty AP, Mannion EM, Moss J et al (2000) Spread of silicone to inguinal lymph nodes from a leaking testicular prosthesis: a cause for chronic fatigue? BJU Int 86:1090PubMedCrossRef
8.
Zurück zum Zitat John TT, Fordham MV (2003) Spontaneous rupture of testicular prosthesis with external leakage of silicone—a rare event. J Urol 170:1306PubMedCrossRef John TT, Fordham MV (2003) Spontaneous rupture of testicular prosthesis with external leakage of silicone—a rare event. J Urol 170:1306PubMedCrossRef
10.
Zurück zum Zitat Lappe MA (1993) Silicone-reactive disorder: a new autoimmune disease caused by immunostimulation and superantigens. Med Hypotheses 41:348PubMedCrossRef Lappe MA (1993) Silicone-reactive disorder: a new autoimmune disease caused by immunostimulation and superantigens. Med Hypotheses 41:348PubMedCrossRef
11.
Zurück zum Zitat Aynsley-Green A, Zachmann M, Illig R et al (1976) Congenital bilateral anorchia in childhood: a clinical, endocrine and therapeutic evaluation of twenty-one cases. Clin Endocrinol (Oxf) 5:381CrossRef Aynsley-Green A, Zachmann M, Illig R et al (1976) Congenital bilateral anorchia in childhood: a clinical, endocrine and therapeutic evaluation of twenty-one cases. Clin Endocrinol (Oxf) 5:381CrossRef
12.
Zurück zum Zitat Bernasconi S, Ghizzoni L, Panza C et al (1992) Congenital anorchia: natural history and treatment. Horm Res 37(Suppl 3):50PubMed Bernasconi S, Ghizzoni L, Panza C et al (1992) Congenital anorchia: natural history and treatment. Horm Res 37(Suppl 3):50PubMed
13.
14.
15.
Zurück zum Zitat Jockenhovel F, Vogel E, Kreutzer M et al (1996) Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. Clin Endocrinol (Oxf) 45:61CrossRef Jockenhovel F, Vogel E, Kreutzer M et al (1996) Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. Clin Endocrinol (Oxf) 45:61CrossRef
16.
Zurück zum Zitat Ebert T, Jockenhovel F, Morales A et al (2005) The current status of therapy for symptomatic late-onset hypogonadism with transdermal testosterone gel. Eur Urol 47:137PubMedCrossRef Ebert T, Jockenhovel F, Morales A et al (2005) The current status of therapy for symptomatic late-onset hypogonadism with transdermal testosterone gel. Eur Urol 47:137PubMedCrossRef
17.
Zurück zum Zitat Schubert M, Minnemann T, Hubler D et al (2004) Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 89:5429PubMedCrossRef Schubert M, Minnemann T, Hubler D et al (2004) Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 89:5429PubMedCrossRef
18.
Zurück zum Zitat Darby E, Anawalt BD (2005) Male hypogonadism: an update on diagnosis and treatment. Treat Endocrinol 4:293–309PubMedCrossRef Darby E, Anawalt BD (2005) Male hypogonadism: an update on diagnosis and treatment. Treat Endocrinol 4:293–309PubMedCrossRef
19.
Zurück zum Zitat Mazer NA, Shifren JL (2003) Transdermal testosterone for women: a new physiological approach for androgen therapy. Obstet Gynecol Surv 58:489PubMed Mazer NA, Shifren JL (2003) Transdermal testosterone for women: a new physiological approach for androgen therapy. Obstet Gynecol Surv 58:489PubMed
20.
Zurück zum Zitat Wang C, Swerdloff RS, Iranmanesh A et al (2000) Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 85:2839PubMedCrossRef Wang C, Swerdloff RS, Iranmanesh A et al (2000) Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 85:2839PubMedCrossRef
21.
Zurück zum Zitat Weil J, Bidlingmaier F, Butenandt O et al (1980) Treatment of anorchia with oral testosterone undecanoate: pharmacodynamics and clinical effectiveness. Acta Endocrinol (Copenh) 95:244 Weil J, Bidlingmaier F, Butenandt O et al (1980) Treatment of anorchia with oral testosterone undecanoate: pharmacodynamics and clinical effectiveness. Acta Endocrinol (Copenh) 95:244
22.
Zurück zum Zitat Zachmann M (1991) Therapeutic indications for delayed puberty and hypogonadism in adolescent boys. Horm Res 36:141PubMedCrossRef Zachmann M (1991) Therapeutic indications for delayed puberty and hypogonadism in adolescent boys. Horm Res 36:141PubMedCrossRef
23.
Zurück zum Zitat Amiel GE, Atala A (1999) Current and future modalities for functional renal replacement. Urol Clin North Am 26:235PubMedCrossRef Amiel GE, Atala A (1999) Current and future modalities for functional renal replacement. Urol Clin North Am 26:235PubMedCrossRef
24.
25.
Zurück zum Zitat Atala A, Cima LG, Kim W et al (1993) Injectable alginate seeded with chondrocytes as a potential treatment for vesicoureteral reflux. J Urol 150:745PubMed Atala A, Cima LG, Kim W et al (1993) Injectable alginate seeded with chondrocytes as a potential treatment for vesicoureteral reflux. J Urol 150:745PubMed
26.
Zurück zum Zitat Amiel GE, Yoo JJ, Kim BS et al (2001) Tissue engineered stents created from chondrocytes. J Urol 165:2091PubMedCrossRef Amiel GE, Yoo JJ, Kim BS et al (2001) Tissue engineered stents created from chondrocytes. J Urol 165:2091PubMedCrossRef
27.
Zurück zum Zitat Yoo JJ, Atala A (2002) Tissue engineering of genitourinary organs. Ernst Schering Res Found Workshop, p 105 Yoo JJ, Atala A (2002) Tissue engineering of genitourinary organs. Ernst Schering Res Found Workshop, p 105
28.
Zurück zum Zitat Yoo JJ, Park HJ, Lee I et al (1999) Autologous engineered cartilage rods for penile reconstruction. J Urol 162:1119PubMedCrossRef Yoo JJ, Park HJ, Lee I et al (1999) Autologous engineered cartilage rods for penile reconstruction. J Urol 162:1119PubMedCrossRef
29.
Zurück zum Zitat Kim BS, Yoo JJ, Atala A (2002) Engineering of human cartilage rods: potential application for penile prostheses. J Urol 168:1794PubMedCrossRef Kim BS, Yoo JJ, Atala A (2002) Engineering of human cartilage rods: potential application for penile prostheses. J Urol 168:1794PubMedCrossRef
30.
Zurück zum Zitat Lin YM, Poon SL, Choi JH et al (2007) Transcripts of testicular gonadotropin-releasing hormone, steroidogenic enzymes, and intratesticular testosterone levels in infertile men. Fertil Steril, Epub ahead of print, Dec 13 2007 Lin YM, Poon SL, Choi JH et al (2007) Transcripts of testicular gonadotropin-releasing hormone, steroidogenic enzymes, and intratesticular testosterone levels in infertile men. Fertil Steril, Epub ahead of print, Dec 13 2007
31.
Zurück zum Zitat Miechi HR, Turner D, Guitelman A et al (1975) Pituitary-gonadal response to acute I.M. stimulation with clomiphene citrate in normal men. J Clin Endocrinol Metab 40:1114PubMed Miechi HR, Turner D, Guitelman A et al (1975) Pituitary-gonadal response to acute I.M. stimulation with clomiphene citrate in normal men. J Clin Endocrinol Metab 40:1114PubMed
32.
Zurück zum Zitat Schalch DS, Parlow AF, Boon RC et al (1968) Measurement of human luteinizing hormone in plasma by radioimmunoassay. J Clin Invest 47:665PubMed Schalch DS, Parlow AF, Boon RC et al (1968) Measurement of human luteinizing hormone in plasma by radioimmunoassay. J Clin Invest 47:665PubMed
33.
Zurück zum Zitat Turek PJ, Master VA (2004) Safety and effectiveness of a new saline filled testicular prosthesis. J Urol 172:1427PubMedCrossRef Turek PJ, Master VA (2004) Safety and effectiveness of a new saline filled testicular prosthesis. J Urol 172:1427PubMedCrossRef
34.
Zurück zum Zitat Atala A, Kim W, Paige KT et al (1994) Endoscopic treatment of vesicoureteral reflux with a chondrocyte-alginate suspension. J Urol 152:641PubMed Atala A, Kim W, Paige KT et al (1994) Endoscopic treatment of vesicoureteral reflux with a chondrocyte-alginate suspension. J Urol 152:641PubMed
35.
Zurück zum Zitat Yoo JJ, Atala A (2000) Tissue engineering applications in the genitourinary tract system. Yonsei Med J 41:789PubMed Yoo JJ, Atala A (2000) Tissue engineering applications in the genitourinary tract system. Yonsei Med J 41:789PubMed
36.
Zurück zum Zitat Yoo JJ, Meng J, Oberpenning F et al (1998) Bladder augmentation using allogenic bladder submucosa seeded with cells. Urology 51:221PubMedCrossRef Yoo JJ, Meng J, Oberpenning F et al (1998) Bladder augmentation using allogenic bladder submucosa seeded with cells. Urology 51:221PubMedCrossRef
Metadaten
Titel
Tissue engineered testicular prostheses with prolonged testosterone release
verfasst von
Atlantida M. Raya-Rivera
Carlos Baez
Anthony Atala
James J. Yoo
Publikationsdatum
01.08.2008
Verlag
Springer-Verlag
Erschienen in
World Journal of Urology / Ausgabe 4/2008
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-008-0267-y

Weitere Artikel der Ausgabe 4/2008

World Journal of Urology 4/2008 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.